Sunny Pharmtech Pharmaceuticals is accelerating its global sales expansion. The gynecological drug CPT injectable product has seen its first shipment to the United Arab Emirates this month, with the second batch expected to be shipped by the end of the year. Additionally, there has been an increase in orders for the anti-cancer injectable CPA-I, with hopes to achieve a 15% market share this year. Next year, the company plans to enter markets outside the United States, such as Mexico. Sunny Pharmtech also revealed that a soft capsule product developed in collaboration with domestic partners will soon sign a distribution agreement in the United States. With steady growth in the first half of this year and concentrated shipments in the second half, along with contributions from milestone payments, the company expects further revenue growth.
Sunny Pharmtech is accelerating its global strategy of "one drug, multiple indications." Chairman Wu Yong-lian stated today that seven products are already listed in the U.S. market, with particular optimism for the growth performance of CPA-I, which was launched at the end of last year and is still being distributed. The market is approximately $87 million, with a current market share of around 10%. The company aims to increase this to 15% this year. Wu revealed that originally, shipments were planned quarterly, but now there are additional orders for the third quarter, with confirmation still pending for the fourth quarter. Next year, the company will enter other markets, with Mexico already signing a distribution agreement. Production will transition from semi-automatic to fully automatic to meet growing demand, expected to be completed by September at the earliest.
In addition to continued sales in the U.S. market, the gynecological drug CPT injectable product is expanding into markets outside the U.S. The United Arab Emirates contract has already been secured, with the first shipment this month and the second expected by year-end. The UK has also signed with distributors and is starting the drug registration process. Another hemostatic agent expected to launch in the second quarter will also contribute to momentum.
Wu Yong-lian revealed that the soft capsule product developed in collaboration with domestic pharmaceutical companies has been completed, and a three-way profit-sharing distribution agreement will be signed with U.S. distributors shortly, followed by drug registration and factory inspection procedures.
The operating outlook for this year is optimistic. Wu Yong-lian said that steady growth in the first half of the year, coupled with concentrated shipments of some CDMO and CMO projects and milestone payments in the second half, will significantly strengthen the growth momentum in the second half of the year. Analysts estimate that revenue will grow by more than 30% this year, with operations aiming for profitability in the fourth quarter.
Resource (Mandarin):
